Protocol Ledger

NCT03588091 · Phase III · COMPLETED

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Interventional Phase III clinical trial protocol NCT03588091 sponsored by Jiangsu HengRui Medicine Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-07-24 Enrollment: 355 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03588091
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)355 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03588091
Protocol FieldVerified Registry Value
NCT IdentifierNCT03588091
Consolidated Lead SponsorJiangsu HengRui Medicine Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment355 participants (ACTUAL)
Registered Start Date2018-07-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI